Results 71 to 80 of about 31,601 (273)
Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All
Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic +2 more
wiley +1 more source
JPGN Reports, EarlyView.Abstract Objective Multidisciplinary care is recommended for pediatric inflammatory bowel disease (IBD). This study aims to describe provider attitudes, barriers, and facilitators regarding multidisciplinary care in pediatric IBD, and explore associations between multidisciplinary care access and center‐level factors.
Nicole Davidson +6 more
wiley +1 more source
Pharmaceuticals, 2020 Drug budget and prescription control measures are implemented regionally in Germany, meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region.
Evelien Moorkens +8 more
doaj +1 more source
Biases affecting injected doses of an experimental drug during clinical trials. [PDF]
, 2016 During clinical trials, researchers rarely question nominal doses specified on labels of investigational products, overlooking the potential for inaccuracies that may result when calculating pharmacokinetic and pharmacodynamic parameters.
Biollaz, J. +6 more
core +2 more sources
Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat. [PDF]
PLoS ONE, 2016 The similarity between a proposed biosimilar product and the reference product can be affected by many factors. This study is designed to examine whether any subtle difference in the distribution of the charge variants of an Avastin biosimilar can affect
Yan-Yan Zhao +5 more
doaj +1 more source
Predictive glycoengineering of biosimilars using a Markov chain glycosylation model [PDF]
, 2016 Biosimilar drugs must closely resemble the pharmacological attributes of innovator products to ensure safety and efficacy to obtain regulatory approval. Glycosylation is one critical quality attribute that must be matched, but it is inherently difficult ...
Hansen, Anders Holmgaard +4 more
core +1 more source
New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa
JEADV Clinical Practice, EarlyView.ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender +2 more
wiley +1 more source
THE NOVEL BIOSIMILAR OF FOLLITROPIN ALPHA TO BE MANUFACTURED IN RUSSIA STARTING FROM 2017
Акушерство, гинекология и репродукция, 2017 Within the framework of the 27th international conference «Reproductive technologies today and tomorrow», the first Russia-made follitropin alfa biosimilar for controlled ovarian stimulation in assisted reproductive technologies (ART) was presented.
I. I. Vorobiev +2 more
doaj +1 more source
PMS62 A Multi-Country Physician Survey On Patient Eligibility And Use Of Biologics In Rheumatoid Arthritis (Ra), Ankylosing Spondylitis (As) And Psoriatic Arthritis (Psa) In European Union (Eu) [PDF]
, 2013 Item does not contain ...
Narayanan, S. +3 more
core +1 more source
The Laryngoscope, EarlyView.ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best +17 more
wiley +1 more source